For US Healthcare Professionals Only
Congress Materials
FILTER
FILTER
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
A matching-adjusted indirect comparison of the efficacy of bimekizumab and guselkumab at 52 weeks for the treatment of psoriatic arthritis
Achievement of Low Disease Activity Over 52 Weeks in Patients with Active Axial Spondyloarthritis on Bimekizumab Treatment: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
An Exploratory Analysis of the Potential Disconnect Between Objective Inflammatory Response and Clinical Response Following Certolizumab Pegol Treatment in Patients with Active Axial Spondyloarthritis
Association of DLQI 0/1 with absolute PASI by age and sex in patients with psoriasis treated with certolizumab pegol: Three-year results from three phase 3 trials
Association of EQ VAS with treatment benefits and patient-reported benefits in patients with moderate to severe psoriasis – data from the German national psoriasis registry PsoBest
Poster Winter Clinical Miami, 2024
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Poster Maui Derm Hawaii, 2024
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year efficacy in high-impact areas in moderate to severe plaque psoriasis: Pooled results from five phase 3/3b trials
Poster Winter Clinical Miami, 2024
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Poster Maui Derm Hawaii, 2024
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year maintenance of response in Week 16 responders with moderate to severe plaque psoriasis: Results from five phase 3/3b trials
Poster Winter Clinical Miami, 2024
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Poster Maui Derm Hawaii, 2024
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Poster Winter Clinical Hawaii, 2024
Bimekizumab 3-year safety and tolerability in moderate to severe plaque psoriasis: Long-term pooled analysis from five phase 3/3b trials
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Bimekizumab Achieved Sustained Improvements in Efficacy Outcomes in Patients with Axial Spondyloarthritis, Regardless of Prior TNF Inhibitor Treatment: Week 52 Pooled Results from Two Phase 3 Studies
Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year
Bimekizumab clinical efficacy translates into benefits in patient-perceived symptoms and quality of life in patients with moderate to severe plaque psoriasis: Two-year data from BE RADIANT
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Poster Maui Derm NP + PA Fall, 2023
Bimekizumab continuous maintenance of response at every visit through two years in patients with moderate to severe plaque psoriasis: Post-hoc results from five phase 3/3b trials
Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials
Poster Fall Clinical PA + NP, 2023
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab efficacy and safety in biologic DMARD-naïve patients with psoriatic arthritis was consistent with or without methotrexate: 52-Week results from the Phase 3 active reference study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Bimekizumab Efficacy and Safety in Biologic DMARD-Naïve Patients with Psoriatic Arthritis was Consistent With or Without Methotrexate: 52-Week Results from the Phase 3 Active Reference Study BE OPTIMAL
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study
Oral Presentation European Academy of Dermatology & Venereology (EADV), 2023
Bimekizumab Efficacy and Safety in Patients with Active Psoriatic Arthritis and Psoriasis: 52-Week Results from the BE OPTIMAL and BE COMPLETE Phase 3 Randomised, Placebo-Controlled Studies
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension
Bimekizumab Efficacy by Disease Duration in Patients with Moderate to Severe Hidradenitis Suppurativa: Week 48 Results from BE HEARD I & II
Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index or hyperglycaemia: Results through one year of treatment in four phase 3/3b trials
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis and hypertension, elevated body mass index, or hyperglycemia: Results through 3 years of treatment in 5 phase 3/3b trials
Bimekizumab efficacy in patients with moderate to severe plaque psoriasis: Psoriasis Symptoms and Impacts Measure (P-SIM) results across 14 items through Week 16 of three pivotal phase 3 trials
Bimekizumab efficacy through 144 weeks in moderate to severe plaque psoriasis: Patient-reported outcomes from BE RADIANT
Bimekizumab efficacy through 3 years in patients with moderate to severe plaque psoriasis: Long-term pooled analysis from BE BRIGHT
Poster Winter Clinical Miami, 2024
Bimekizumab efficacy through Year 1 in patients with moderate to severe plaque psoriasis who had not achieved a PASI 90 response by Week 16: A pooled analysis from four phase 3/3b trials
Bimekizumab impact on cardiovascular inflammation markers in moderate to severe plaque psoriasis: Results from phase 3 trials
Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II
Bimekizumab Impact on Core Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) Domains for Patients with Psoriatic Arthritis: 52-Week Results from Four Phase 3 Studies
Bimekizumab Impact on Dichotomous IHS4 Response Levels in Patients with Moderate to Severe Hidradenitis Suppurativa: Results up to Week 48 from BE HEARD I & II
Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II
Bimekizumab Impact on Health-Related Quality of Life and Physical Function in Patients with Active Psoriatic Arthritis who were Biologic DMARD-Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3, Randomized
Bimekizumab impact on joint and pain outcomes in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab Impact on Lesion Count by Anatomical Region in Moderate to Severe Hidradenitis Suppurativa: Results to Week 48 from BE HEARD I & II
Bimekizumab improved outcomes in disease core domains in patients with active psoriatic arthritis and psoriasis: Pooled 16-week results from the BE OPTIMAL and BE COMPLETE phase 3 randomised, placebo-controlled studies
Bimekizumab Improved Physical Function and Health-Related Quality of Life in Patients with Axial Spondyloarthritis: 52-Week Results from Two Phase 3 Studies
Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis
Bimekizumab improves key patient-reported symptoms of axial spondyloarthritis including spinal pain and fatigue: Results from two phase 3 studies
Bimekizumab in patients with active non-radiographic and radiographic axial spondyloarthritis: 52-week efficacy and safety from the BE MOBILE phase 3 studies
Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: A Focus on Patient Quality of Life and Depth of Responses from BE HEARD I & II to Week 48
Bimekizumab in patients with moderate to severe plaque psoriasis: Analysis of mental health and associated disorders
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis who were Responders at Week 16: Results from a Phase 3, Active Reference Study
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Biologic Disease-Modifying Antirheumatic Drug-Naïve Patients with Psoriatic Arthritis Who Were Responders at Week 16: Results from BE OPTIMAL, a Phase 3, Active Reference Study
Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Psoriatic Arthritis and Inadequate Response or Intolerance to TNF-α Inhibitors who were Responders at Week 16: Results from a Phase 3, Randomized Study
Bimekizumab Maintained Improvements in Efficacy Endpoints and Had a Consistent Safety Profile Through 52 Weeks in Patients with Axial Spondyloarthritis: Results from Two Parallel Phase 3 Studies
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Bimekizumab Maintained Stringent Clinical Responses Through Week 52 in Patients with Axial Spondyloarthritis: Results from the Phase 3 Studies BE MOBILE 1 and BE MOBILE 2
Poster Fall Clinical PA + NP, 2023
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open-label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bimekizumab Maintenance of Response and Safety in Patients with Moderate to Severe Plaque Psoriasis: Results from the Open-label Extension Period (Weeks 48–144) of the BE RADIANT Phase 3b Trial
Poster DERM 2023 NP/PA CME, 2023
Bimekizumab maintenance of response and safety in patients with moderate to severe plaque psoriasis: Results from the open‑label extension period (Weeks 48–144) of the BE RADIANT phase 3b trial
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Bimekizumab Reduced MRI Inflammatory Lesions in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and 2 Phase 3 Studies
Poster Winter Clinical Miami, 2024
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response maintenance to 48 weeks in patients with moderate to severe hidradenitis suppurativa: Pooled responder analysis from the phase 3, double-blind, placebo-controlled, randomized clinical trials BE HEARD I & II
Bimekizumab response through 3 years in patients with plaque psoriasis who stopped and re-started treatment
Bimekizumab response through three years of treatment in patients with moderate to severe plaque psoriasis who responded after 16 weeks: Results from the open-label extension of BE RADIANT
Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Infection rates using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab safety in patients with moderate to severe plaque psoriasis: Safety topics of interest over time using pooled data from up to three years of treatment in five phase 3/3b clinical trials
Bimekizumab speed of response in patients with moderate to severe plaque psoriasis: Results from four phase 3/3b trials (BE VIVID, BE READY, BE SURE, and BE RADIANT)
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Bimekizumab Treatment Impact on Pain and Fatigue in Patients with Active Psoriatic Arthritis who were Biologic DMARD‑Naïve or had Inadequate Response or Intolerance to TNF-α Inhibitors: 1-Year Results from Two Phase 3 Studies
Bimekizumab Treatment Impact on Work Productivity in Biologic DMARD-Naïve and TNFi-IR Patients with Active Psoriatic Arthritis: Results up to 1 Year from Two Phase 3 Studies
Bimekizumab Treatment Improved Key Patient-Reported Symptoms of Axial Spondyloarthritis Including Spinal Pain, Fatigue, and Morning Stiffness: 52-Week Results from Two Phase 3 Studies
Bimekizumab Treatment in Patients with Active PsA and Prior Inadequate Response to TNF Inhibitors: Sustained Efficacy and Safety Results from a Phase 3 Study and its Open-Label Extension up to 1 Year
Bimekizumab Treatment Resulted in Clinically Meaningful Improvements in the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Scores Using Pooled Results from Two Phase 3 Trials in Patients with Psoriatic Arthritis
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies
Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies
Oral Presentation American Academy of Dermatology (AAD), 2024
Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies
Poster Winter Clinical Miami, 2024
Bimekizumab versus secukinumab continuous maintenance of PASI 90 and PASI 100 responses through one year in patients with moderate to severe plaque psoriasis: Post-hoc results from the BE RADIANT phase 3b trial
Bimekizumab versus Secukinumab for the Treatment of Nail Psoriasis in Patients with Moderate to Severe Plaque Psoriasis: Results from the BE RADIANT Phase 3b Trial
Bimekizumab-Treated Patients with Active PsA Showed Sustained Improvement in Disease Symptoms Assessed by the PsA Impact of Disease (PsAID)-12 Questionnaire: 1-Year Results Reported from Two Phase 3 Studies
Comparison of Established and New, Preliminarily Proposed ASAS Cut-Offs for Inflammatory MRI Lesions in the Sacroiliac Joints in Axial Spondyloarthritis and Implications for Recruitment in Clinical Studies
Poster RheumNow Live! (RNL), 2024
Durability of response among patients with psoriatic arthritis (PsA) using biological or targeted synthetic disease-modifying antirheumatic drugs in the CorEvitas PsA/spondyloarthritis registry
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Early responders with zilucoplan: An interim analysis of RAISE-XT in patients with generalized myasthenia gravis
Effect of zilucoplan on disease fluctuation in patients with generalized myasthenia gravis in the Phase 3 RAISE study
Effect of zilucoplan on fatigue in generalized myasthenia gravis in the Phase 3 RAISE and RAISE-XT studies
Efficacy of Certolizumab Pegol in Preventing Anterior Uveitis Flares Compared with Standard Non-Biologic Treatment: A Matched Control Study in High-Risk Patients with Axial Spondyloarthritis
Efficacy of repeated cycles of rozanolixizumab treatment in subgroups of patients with generalized myasthenia gravis: A pooled analysis of a Phase 3 study and two Phase 3 open-label extension studies
Identification of Responder and Disease Activity Thresholds for the Psoriatic Arthritis Impact of Disease-12 (PsAID-12) Questionnaire Using Pooled Data from Two Phase 3 Trials of Bimekizumab in Patients with Psoriatic Arthritis
IHS4 Outcomes with Bimekizumab in Patients with Moderate to Severe Hidradenitis Suppurativa: Pooled Results from the BE HEARD I & II Phase 3 Trials
Impact of the CIMplicity® Patient Support Program on Persistence to Certolizumab Pegol Treatment: A Retrospective Cohort Analysis of Claims Data in the United States
Itching, skin pain and scaling in patients with plaque psoriasis: The relationship between improvements in Psoriasis Area and Severity Index and Psoriasis Symptoms and Impacts Measure responses
Long-Term Safety and Efficacy of Bimekizumab in Patients with Active Ankylosing Spondylitis: 5-Year Results from a Phase 2b Study and its Open-Label Extension
Poster RheumNow Live! (RNL), 2024
Long-term safety and efficacy of bimekizumab in patients with active ankylosing spondylitis: 5-year results from a phase 2b study and its open-label extension
Long-Term Safety and Tolerability of Bimekizumab in Patients with Axial Spondyloarthritis and Psoriatic Arthritis: Results from Pooled Phase 2b/3 Studies
Long-term safety of repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis
Looking beyond the numbers: Interpreting patient experience of rozanolixizumab in generalized myasthenia gravis from the MycarinG clinical trial
Low Uveitis Rates in Patients with Axial Spondyloarthritis Treated with Bimekizumab: Pooled Results from Phase 2b/3 Trials
Management and treatment patterns in psoriasis and psoriatic arthritis
MG-ADL and QMG scores over time in patients with generalized myasthenia gravis: Post-hoc analysis of MycarinG and open-label studies
Oral Presentation American Academy of Dermatology (AAD), 2024
Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment
Patient and Physician Preferences for Attributes Associated with Biologic Treatments for Hidradenitis Suppurativa
Patient-reported outcomes during repeated cycles of rozanolixizumab treatment in patients with generalized myasthenia gravis in the Phase 3 MycarinG and open-label extension studies
Patients with psoriatic arthritis at biologic therapy switch: The CorEvitas psoriasis registry
Patients with Psoriatic Arthritis at Biologic Therapy Switch: The CorEvitas Psoriasis Registry
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Performance Analysis of a Deep Learning Algorithm to Detect Positive SIJ MRI According to the ASAS Definition in axSpA Patients
Real world data on the 1-year treatment of psoriasis with the use of certolizumab pegol in women of child-bearing potential
Real-world data on the use of certolizumab pegol for the treatment of moderate to severe plaque psoriasis: 1-year results from a prospective non-interventional cohort study
Real-world patient characteristics and prior treatment history of bimekizumab patients in Germany
Repeated cycles of rozanolixizumab treatment in patients with muscle-specific kinase autoantibody-positive generalized myasthenia gravis
Resolution of Enthesitis and Peripheral Arthritis with Bimekizumab in Patients with Axial Spondyloarthritis: Week 52 Results from the BE MOBILE 1 and BE MOBILE 2 Phase 3 Studies
Response rates with zilucoplan among patients with generalized myasthenia gravis in an interim analysis of RAISE-XT, a Phase 3 open-label extension study
Rheumatology Care Journey Among Patients with Psoriatic Arthritis or Axial Spondyloarthritis in the United States
Risk of myasthenia gravis exacerbation and level of healthcare resource utilization by Myasthenia Gravis Activities of Daily Living score
Self-reported pain outcomes in patients with moderate to severe plaque psoriasis treated with certolizumab pegol: Three-year results from two phase 3 trials (CIMPASI-1 and CIMPASI-2)
Social determinants of health are associated with suboptimal treatment among individuals with myasthenia gravis
Stable plasma concentration of certolizumab pegol is associated with persistent clinical improvement among patients with moderate to severe plaque psoriasis: Data from CIMPASI-1 and CIMPASI-2
Subcutaneous rozanolixizumab in pediatric patients with generalized myasthenia gravis: Clinical study design
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumor necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Poster Maui Derm NP + PA Fall, 2023
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the phase 3 BE COMPLETE Study and its open-label extension up to 1 year
Sustained Efficacy and Safety of Bimekizumab in Patients with Active Psoriatic Arthritis and Prior Inadequate Response to Tumour Necrosis Factor Inhibitors: Results from the Phase 3 BE COMPLETE Study and its Open-Label Extension up to 1 Year
Poster DERM 2023 NP/PA CME, 2023
Sustained efficacy and safety of bimekizumab in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: Results from the Phase 3 BE COMPLETE study and its open-label extension up to 1 year
Temporal impact of infection-related treatment emergent adverse events on patient-reported outcomes in patients with moderate to severe psoriasis – analysis of the German national registry PsoBest
Treatment history and symptom severity in patients with moderate to severe plaque psoriasis being initiated on bimekizumab: Use during the 1st year of routine clinical practice
Treatment Journey of Patients with Non-Radiographic Axial Spondyloarthritis in a US Rheumatology Office Setting: A Retrospective Chart Review
Medical Symposium Congress of Clinical Rheumatology (CCR) East, 2023
Understanding the Pathobiology of Axial Spondyloarthritis and Psoriatic Arthritis
Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment Over 52 Weeks: Results from Two Phase 3 Studies
Zilucoplan in pediatric patients with acetylcholine receptor autoantibody positive generalized myasthenia gravis: ziMyG (MG0014) and ziMyG + (MG0015) clinical study designs